The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms

References (155)

1. 1 Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor [DOI]
2. 2 The endogenous cannabinoid system controls extinction of aversive memories [DOI]
3. 3 The orphan receptor GPR55 is a novel cannabinoid receptor [DOI]
4. 4 The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis [DOI]
5. 5 Bilateral brain processes for comprehending natural language [DOI]
6. 6 Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis [DOI]
7. 7 Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain [DOI]
8. 8 The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis [DOI]
9. 9 To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test [DOI]
10. 10 Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects [DOI]
11. 11 Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain [DOI]
12. 12 Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing [DOI]
13. 13 Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.
14. 14 Novel cannabinoid receptors [DOI]
15. 15 Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug [DOI]
16. 16 The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. [DOI]
17. 17 Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1Areceptors [DOI]
18. 18 Neurobiology of Dopamine in Schizophrenia [DOI]
19. 19 Cannabidiol for the treatment of psychosis in Parkinson’s disease [DOI]
20. 20 Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study [DOI]
21. 21 Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol [DOI]
22. 22 The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence [DOI]
23. 23 Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice [DOI]
24. 24 Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats [DOI]
25. 25 Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders [DOI]
26. 26 On the Preparations of the Indian Hemp, or gunjah: Cannabis Indica Their Effects on the Animal System in Health, and their Utility in the Treatment of Tetanus and other Convulsive Diseases [DOI]
27. 27 Comprehension of metaphor and irony in schizophrenia during remission: The role of theory of mind and IQ [DOI]
28. 28 Endocannabinoid system dysfunction in mood and related disorders [DOI]
29. 29 Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction [DOI]
30. 30 Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells [DOI]
31. 31 The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids [DOI]
32. 32 The Functional Output of the Mesolimbic Dopamine System [DOI]
33. 33 Cannabinoids: A New Group of Agonists of PPARs [DOI]
34. 34 Anandamide hydrolysis: a new target for anti-anxiety drugs? [DOI]
35. 35 Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice [DOI]
36. 36 Psychotic Symptoms in Parkinson's Disease Patients with Dementia [DOI]
37. 37 Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test [DOI]
38. 38 Cannabidiol reverses the reduction in social interaction produced by low dose Δ9-tetrahydrocannabinol in rats [DOI]
39. 39 Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia [DOI]
40. 40 Endocannabinoid system: An overview of its potential in current medical practice.
41. 41 Lexical ambiguity resolution in Wernicke's area and its right homologue [DOI]
42. 42 Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum [DOI]
43. 43 Neuromorphological background of cannabis addiction [DOI]
44. 44 Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop [DOI]
45. 45 Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia [DOI]
46. 46 PPAR-γ: A nuclear receptor with affinity for cannabinoids [DOI]
47. 47 Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme [DOI]
48. 48 The endocannabinoid system as a target for modelling psychosis [DOI]
49. 49 Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro [DOI]
50. 50 Marijuana in medicine: past, present and future.
51. 51 Molecular characterization of a peripheral receptor for cannabinoids [DOI]
52. 52 Structure of a cannabinoid receptor and functional expression of the cloned cDNA [DOI]
53. 53 Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans [DOI]
54. 54 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors [DOI]
55. 55 Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [DOI]
56. 56 Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro [DOI]
57. 57 The pharmacology of cannabinoid receptors and their ligands: an overview [DOI]
58. 58 Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression [DOI]
59. 59 Elevated endogenous cannabinoids in schizophrenia [DOI]
60. 60 Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action [DOI]
61. 61 Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders [DOI]
62. 62 Antianxiety effect of cannabidiol in the elevated plus-maze [DOI]
63. 63 5‐HT1Areceptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats [DOI]
64. 64 Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia [DOI]
65. 65 Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons [DOI]
66. 66 Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia [DOI]
67. 67 Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology* [DOI]
68. 68 Cannabis with high cannabidiol content is associated with fewer psychotic experiences [DOI]
69. 69 Anandamide: some like it hot [DOI]
70. 70 A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice [DOI]
71. 71 Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition [DOI]
72. 72 Cannabidiol monotherapy for treatment-resistant schizophrenia [DOI]
73. 73 Effects of cannabidiol in animal models predictive of antipsychotic activity [DOI]
74. 74 Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia [DOI]
75. 75 The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors [DOI]
76. 76 Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice [DOI]
77. 77 Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man [DOI]
78. 78 Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study [DOI]
79. 79 Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress [DOI]
80. 80 The Hippocampus and Nucleus Accumbens as Potential Therapeutic Targets for Neurosurgical Intervention in Schizophrenia [DOI]
81. 81 Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update [DOI]
82. 82 Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent [DOI]
83. 83 The absolute configuration of δ1-tetrahydrocannabinol, the major active constituent of hashish. [DOI]
84. 84 Complex pharmacology of natural cannabivoids: Evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors [DOI]
85. 85 CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES [DOI]
86. 86 Involvement of the Pallidal‐thalamocortical Circuit in Adaptive Behavior [DOI]
87. 87 Inhibition of Anandamide Amidase Activity in Mouse Brain Microsomes by Cannabinoids. [DOI]
88. 88 Reduced binocular depth inversion in schizophrenic patients [DOI]
89. 89 Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze [DOI]
90. 90 EFFECTS OF MARIHUANA IN LABORATORY ANIMALS AND IN MAN [DOI]
91. 91 Uso terapêutico dos canabinoides em psiquiatria [DOI]
92. 92 The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects [DOI]
93. 93 Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania [DOI]
94. 94 Cannabinoid-induced alterations in brain disposition of drugs of abuse 11Abbreviations: THC, tetrahydrocannabinol; CBD, cannabidiol; PCP, phencyclidine; MDMA, 3,4-methylenedioxyphenyl-methamphetamine HCl. [DOI]
95. 95 Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats [DOI]
96. 96 Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats [DOI]
97. 97 CB1 receptors diminish both Ca2+ influx and glutamate release through two different mechanisms active in distinct populations of cerebrocortical nerve terminals [DOI]
98. 98 Nucleus accumbens to globus pallidus GABA projection: Electrophysiological and iontophoretic investigations [DOI]
99. 99 ACTIVITY OF CANNABIS IN RELATION TO ITS Δ‘‐trans‐TETRAHYDROCANNABINOL CONTENT [DOI]
100. 100 Taxonomy and morphology of uncultivated hemp (Cannabis sativaL.) as weed in Hungary [DOI]
101. 101 Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia [DOI]
102. 102 International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors [DOI]
103. 103 Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review [DOI]
104. 104 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain [DOI]
105. 105 The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin [DOI]
106. 106 Vanilloid (Capsaicin) Receptors and Mechanisms [DOI]
107. 107 Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies [DOI]
108. 108 Role of Endogenous Cannabinoids in Synaptic Signaling [DOI]
109. 109 Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors [DOI]
110. 110 Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia [DOI]
111. 111 Agonistic Properties of Cannabidiol at 5-HT1a Receptors [DOI]
112. 112 Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants [DOI]
113. 113 Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) [DOI]
114. 114 Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb [DOI]
115. 115 Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology [DOI]
116. 116 Neural stem cell proliferation is decreased in schizophrenia, but not in depression [DOI]
117. 117 A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol [DOI]
118. 118 Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder [DOI]
119. 119 The hallucinating brain: A review of structural and functional neuroimaging studies of hallucinations [DOI]
120. 120 High-potency cannabis and the risk of psychosis [DOI]
121. 121 Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent [DOI]
122. 122 Cannabinoids in medicine: A review of their therapeutic potential [DOI]
123. 123 Cannabidiol: An Overview of Some Pharmacological Aspects [DOI]
124. 124 Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms [DOI]
125. 125 Modern antipsychotic drugs: a critical overview [DOI]
126. 126 Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement [DOI]
127. 127 Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra [DOI]
128. 128 Do we still believe in the dopamine hypothesis? New data bring new evidence [DOI]
129. 129 Characteristics of hemp ( Cannabis sativa L.) seed oil [DOI]
130. 130 Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder [DOI]
131. 131 Controlled clinical trial of cannabidiol in Huntington's disease [DOI]
132. 132 Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis [DOI]
133. 133 PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases [DOI]
134. 134 Do patients with schizophrenia exhibit aberrant salience? [DOI]
135. 135 COVER ARTICLE: Archaeological Evidence for the Tradition of Psychoactive Plant Use in the Old World [DOI]
136. 136 A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation [DOI]
137. 137 Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis [DOI]
138. 138 Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing [DOI]
139. 139 Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis [DOI]
140. 140 Neurogenesis and schizophrenia: dividing neurons in a divided mind? [DOI]
141. 141 Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005 [DOI]
142. 142 Postsynaptic origin of CB1‐dependent tonic inhibition of GABA release at cholecystokinin‐positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus [DOI]
143. 143 Dopaminergic Modulation of Prefrontal Cortical Input to Nucleus Accumbens NeuronsIn Vivo [DOI]
144. 144 TRPV1 Receptor Mediates Glutamatergic Synaptic Input to Dorsolateral Periaqueductal Gray (dl-PAG) Neurons [DOI]
145. 145 Δ9‐tetrahydrocannabinol (Δ9‐THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease [DOI]
146. 146 Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague–Dawley rats [DOI]
147. 147 Endocannabinoids and Schizophrenia [DOI]
148. 148 Psychosis in Parkinson’s disease [DOI]
149. 149 Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use [DOI]
150. 150 Cannabis sativa: a planta que pode produzir efeitos indesejáveis e também tratá-los [DOI]
151. 151 Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish [DOI]
152. 152 Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I [DOI]
153. 153 Antipsychotic effect of cannabidiol.
154. 154 Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids [DOI]
155. 155 Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa [DOI]

Cited by 5

Showing 2 of 5 known citations — external sources report more than can currently be individually listed.

Related research

• Low Prevalence of Metabolic Syndrome in a Group of Patients with Chronic Psychotic Disorders Taking Antipsychotic Polypharmacy in Residential Treatment While Adhering to a Mediterranean Diet — shares topic coverage
• Clinical Motivation Experience Practicum at Rehabilitation Center, Boston: A Case Study — shares topic coverage
• Review of the Challenges Facing Management of Patients with Psychotic Disorder and the Need for Mental Health Policies in Nigeria — shares topic coverage
• Perceived Barriers to Help Seeking for Psychosis among Secondary School Students in Lagos, Nigeria — shares topic coverage
• Periodic Catatonia after Thyroid Cancer — shares topic coverage